Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 17 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)RecruitingNCT06261125Phase 2
• A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesRecruitingNCT06258304Phase 1
• A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell CarcinomaRecruitingNCT06256588Phase 3
• Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 TrialRecruitingNCT06256237Phase 2
• Toripalimab Combined With Definitive CCRT for LACC PatientsRecruitingNCT06256224Not applicable
• Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract CancerNot yet recruitingNCT06255262Phase 1/2
• A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior ImmunotherapyRecruitingNCT06255223Phase 2
• Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal CarcinomaRecruitingNCT06254911Phase 2
• Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast CancerNot yet recruitingNCT06254066Phase 2
• Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular CarcinomaNot yet recruitingNCT06253598Phase 2
• Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial CancerRecruitingNCT06253494Phase 1/2
• Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)RecruitingNCT06251492Phase 2
• A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical CancerRecruitingNCT06251388Phase 2
• Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric JunctionRecruitingNCT06250894Phase 2
• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)RecruitingNCT06246916Phase 3
• PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBCRecruitingNCT06245889Phase 2
• Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal CancerRecruitingNCT06245356Phase 2
• Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLCRecruitingNCT06241807Phase 2
• Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical CarcinomaRecruitingNCT06241235Phase 1/2
• A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2RecruitingNCT06240728Phase 1
• A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral BloodRecruitingNCT06240689Phase 2
• Intradermal Ipilimumab and Nivolumab in High Risk Stage II MelanomaRecruitingNCT06240143Phase 1/2
• Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain MetastasesRecruitingNCT06238921Phase 1/2
• Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJCNot yet recruitingNCT06238167Phase 2
• Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung CancerNot yet recruitingNCT06236997Phase 2
• Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell CarcinomaRecruitingNCT06235918Phase 2
• Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid TumorsRecruitingNCT06234397Phase 1
• Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label StudyRecruitingNCT06234007Phase 2
• Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)RecruitingNCT06231680Phase 2
• Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal CancerRecruitingNCT06231017Phase 2
• Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerRecruitingNCT06230471Phase 2
• Adjuvant vs Surgery Only in Early-stage Recurrent NPCRecruitingNCT06228079Phase 3
• Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast CancerRecruitingNCT06227117Phase 2
• Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLCRecruitingNCT06223711Phase 2
• Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJANot yet recruitingNCT06222944Phase 2
• Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast CancerRecruitingNCT06222879Phase 1/2
• A Study of HB0025 Injection in Patients With Advanced Renal CancerRecruitingNCT06222125Phase 2
• Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological TumorsNot yet recruitingNCT06221774Phase 1/2
• DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyRecruitingNCT06221748Phase 2/3
• Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)RecruitingNCT06221670Phase 2
• Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung CancerNot yet recruitingNCT06221462Phase 2
• The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent GlioblastomaRecruitingNCT06220552Phase 2
• A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver MetastasesNot yet recruitingNCT06218888Phase 2
• Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal CancerRecruitingNCT06218810Phase 2
• Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06218004Phase 2
• Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCRecruitingNCT06217757Phase 1/2
• Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular CarcinomaRecruitingNCT06215651Phase 2
• Proteomic Guided First-line Precision Treatment of Renal Clear Cell CarcinomaRecruitingNCT06211790Phase 2
• Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell CarcinomaRecruitingNCT06211335Phase 1
• HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)Not yet recruitingNCT06210334Phase 2
• Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving SurgeryRecruitingNCT06209294Phase 2
• A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With ChemotherapyRecruitingNCT06208826Phase 2
• Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent CancerRecruitingNCT06208657Phase 1/2
• Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence FactorsRecruitingNCT06208462Phase 2
• Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal CancerRecruitingNCT06205836Phase 2
• Drug Screening Using IMD in Bladder CancerEnrolling by invitationNCT06204614Early Phase 1
• Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal CancerRecruitingNCT06204094Phase 2
• Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialRecruitingNCT06203600Phase 2/3
• Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast CancerNot yet recruitingNCT06202313Phase 2
• FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind TrialRecruitingNCT06201065Phase 3
• Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06199271Phase 2
• Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)Not yet recruitingNCT06198907Phase 2
• Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction CarcinomaNot yet recruitingNCT06198465Phase 2
• Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric CancerNot yet recruitingNCT06197438Phase 2
• AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLCNot yet recruitingNCT06196814Phase 1/2
• A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNCT06196775Phase 2
• AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ CancerRecruitingNCT06196697Phase 2
• Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic CholangiocarcinomaRecruitingNCT06192797Phase 2
• Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic CholangiocarcinomaRecruitingNCT06192784Phase 2
• A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCCRecruitingNCT06190639Phase 2
• HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular CarcinomaRecruitingNCT06187961Phase 2
• Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)RecruitingNCT06187597Phase 2
• PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCCRecruitingNCT06186609Phase 2
• A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract MalignanciesRecruitingNCT06181032Phase 1
• A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial CarcinomaRecruitingNCT06178601Phase 2
• Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical TrialNot yet recruitingNCT06178211Phase 2
• A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLCRecruitingNCT06177925Phase 2
• Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic CancerNot yet recruitingNCT06177522Phase 2
• Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal CancerRecruitingNCT06176885Phase 2
• Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal CancerRecruitingNCT06173986Phase 1/2
• A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy AdultsRecruitingNCT06173011Phase 1
• Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCCRecruitingNCT06170710Phase 2
• Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell CarcinomaRecruitingNCT06170697Phase 2
• Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRCRecruitingNCT06168786Phase 2
• A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-TRecruitingNCT06167785Phase 2
• A Study of AK131 in Patients With Advanced Solid TumorsRecruitingNCT06166888Phase 1
• Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic CancerNot yet recruitingNCT06166589Phase 2
• Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBCRecruitingNCT06165900Phase 2
• Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction AdenocarcinomaRecruitingNCT06163729Phase 2
• Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical ResectionNot yet recruitingNCT06161909Phase 3
• Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell CarcinomaRecruitingNCT06161545Phase 2
• A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine CarcinomaRecruitingNCT06157827Phase 1/2
• PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerRecruitingNCT06157151Phase 2
• PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction ChemotherapyRecruitingNCT06156878Phase 2
• Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic AdenocarcinoNot yet recruitingNCT06156267Early Phase 1
• A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical CancerRecruitingNCT06155396Phase 2
• Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT06155383Phase 2
• Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal CancerRecruitingNCT06154538Phase 2
• Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPCNot yet recruitingNCT06153368Phase 2
• A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06152978Phase 2

← Immune Checkpoint Inhibitors overview